Whether it is comfortable “table talk” or not, there are certain aspects of biotechnology stocks, such as anal fissures or sexually transmitted diseases, that produce incredible amounts of revenue each year for the companies behind therapies that treat the given ailment. Erectile dysfunction may not be the most pleasant of conversations for many people, but the bottom line is that Pfizer has generated a great deal of cash since bringing Viagara to market and that reason alone is enough to catch the attention of the investment community.
Vancouver, British Columbia-based Global Health, Inc., a specialty pharmaceutical company with expertise in drug delivery and formulation, is looking to capitalize on the erectile dysfunction market and take some market share from Pfizer’s Viagara. The Company released news that it has completed head-to-head testing of its lead therapeutic drug, X-Excite against Viagara in 24 men. The purpose of these trials was to determine X-Excite’s pharmacokinetics , in addition to tolerability, safety and efficacy, in men on side-by-side study with Pfizer’s well-known drug, Viagra. All the patients completed the trial and the results are presently being studied in a central lab in Amsterdam, Holland. The data is slated to be available at the end of March.
X-Excite is a sublingual formulation of sildenafil citrate which is the basis of Pfizer’s blockbuster drug, Viagra. It has been scientifically proven that sublingual delivery is the fastest way to get a drug into the blood as the drug is absorbed through the tissues of the mouth. In addition to speed in delivery, injections can be eliminated for many therapies and the oral absorption also allows the drug to bypass the liver thus avoiding many of the side effects of drugs which are due to metabolism in the liver. Global Health’s sublingual delivery should have fewer side effects, in theory, than similar erectile dysfunction drugs on the market, including Viagra.
Global Health reported that they plan on entering into discussions regarding partnership possibilities with big pharma after receipt and review of the final results from the new data. Investors appear to still be waiting on the sidelines for the results to come in, although the share price is giving the appearance of trying to find a bottom. Since touching a 52-week low at $0.024 in December 2010, the price per share has held that level and is trying to creep upward. The competition is stiff as many brands are looking to cut into Viagara’s dominance, but perhaps the new oral treatment will be the ticket for Global Health to begin a more sustained push upward.
More information on Global Health, Inc. and its pipeline of products can be found on the Company’s website at www.globalhealth3000.com
Let us hear your thoughts below:
